Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade

BACKGROUND: High-grade sarcomas are a heterogeneous group of aggressive tumors arising in bone and soft tissues. After relapse, treatment options are limited. The multi-targeted receptor tyrosine kinase inhibitors (TKIs) sunitinib and inhibitor of PD-1 (anti-PD-1) nivolumab have shown antitumor acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocadlikova, Darina, Lecciso, Mariangela, Broto, Javier Martin, Scotlandi, Katia, Cavo, Michele, Curti, Antonio, Palmerini, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952316/
https://www.ncbi.nlm.nih.gov/pubmed/33717062
http://dx.doi.org/10.3389/fimmu.2021.577766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952316/
https://www.ncbi.nlm.nih.gov/pubmed/33717062
http://dx.doi.org/10.3389/fimmu.2021.577766

Ejemplares similares